CD44 and neoplasm: These suggest that tumor accumulation of anti-CD44-mAb-IR700 1 day after injection as a target antigen is predicted to be lower in MOC1 tumors and direct cell killing by CD44-targeted PIT is expected to be less efficient compared with MC38-luc or LL/2 tumors.